
Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner

